Ribosomal RNA 2′O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer

Archive ouverte

Marcel, Virginie | Kielbassa, Janice | Marchand, Virginie | Natchiar, Kundhavai s | Paraqindes, Hermes | Nguyen van long, Flora | Ayadi, Lilia | Bourguignon-Igel, Valérie | Lo monaco, Piero | Monchiet, Déborah | Scott, Véronique | Tonon, Laurie | Bray, Susan | Diot, Alexandra | Jordan, Lee | Thompson, Alastair | Bourdon, Jean-Christophe | Dubois, Thierry | André, Fabrice | Catez, Frédéric | Puisieux, Alain | Motorin, Yuri | Klaholz, Bruno , P | Viari, Alain | Diaz, Jean-Jacques

Edité par CCSD ; Oxford University Press -

International audience. Recent epitranscriptomics studies unravelled that ribosomal RNA (rRNA) 2′O-methylation is an additional layer of gene expression regulation highlighting the ribosome as a novel actor of translation control. However, this major finding lies on evidences coming mainly, if not exclusively, from cellular models. Using the innovative next-generation RiboMeth-seq technology, we established the first rRNA 2′O-methylation landscape in 195 primary human breast tumours. We uncovered the existence of compulsory/stable sites, which show limited inter-patient variability in their 2′O-methylation level, which map on functionally important sites of the human ribosome structure and which are surrounded by variable sites found from the second nucleotide layers. Our data demonstrate that some positions within the rRNA molecules can tolerate absence of 2′O-methylation in tumoral and healthy tissues. We also reveal that rRNA 2′O-methylation exhibits intra- and inter-patient variability in breast tumours. Its level is indeed differentially associated with breast cancer subtype and tumour grade. Altogether, our rRNA 2′O-methylation profiling of a large-scale human sample collection provides the first compelling evidence that ribosome variability occurs in humans and suggests that rRNA 2′O-methylation might represent a relevant element of tumour biology useful in clinic. This novel variability at molecular level offers an additional layer to capture the cancer heterogeneity and associates with specific features of tumour biology thus offering a novel targetable molecular signature in cancer.

Suggestions

Du même auteur

Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer

Archive ouverte | Nguyen van Long, Flora | CCSD

International audience. Background: A current critical need remains in the identification of prognostic and predictive markers in early breast cancer. It appears that a distinctive trait of cancer cells is their add...

Druggable Nucleolin Identifies Breast Tumours Associated with Poor Prognosis That Exhibit Different Biological Processes

Archive ouverte | Nguyen van Long, Flora | CCSD

International audience. Background: Nucleolin (NCL) is a multifunctional protein with oncogenic properties. Anti-NCL drugs show strong cytotoxic effects, including in triple-negative breast cancer (TNBC) models, and...

Specific modulation of 28S_Um2402 rRNA 2′-O-ribose methylation as a novel epitranscriptomic marker of ZEB1-induced epithelial–mesenchymal transition in different mammary cell contexts

Archive ouverte | Morin, Chloé | CCSD

International audience. The epithelial–mesenchymal transition (EMT) is a dynamic transdifferentiation of epithelial cells into mesenchymal cells. EMT programs exhibit great diversity, based primarily on the distinct...

Chargement des enrichissements...